Open AccessCombined modality treatment: Outcome in patients with Hodgkin's lymphoma
Author(s) -
Budhi Singh Yadav,
Suresh C. Sharma,
Pankaj Malhotra,
Gaurav Prakash
Publication year - 2020
Publication title -
journal of cancer research and therapeutics/journal of cancer research and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.475
H-Index - 39
eISSN - 0973-1482
pISSN - 1998-4138
DOI - 10.4103/jcrt.jcrt_465_17
Subject(s) - procarbazine , medicine , dacarbazine , abvd , vinblastine , vincristine , stage (stratigraphy) , chemotherapy , radiation therapy , regimen , bleomycin , cyclophosphamide , prednisone , chemotherapy regimen , surgery , gastroenterology , paleontology , biology
Hodgkin's lymphoma (HL) can be treated with combined modality treatment (CMT) to limit long-term toxicities in the early favorable stage. Early unfavorable and advanced stage HL is mainly treated with chemotherapy followed by radiation to the bulky site. This study examines the impact of CMT in early as well as advanced stage HL.